A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak (Coxsackie Virus A21) [CVA 21] Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 [intercellular adhesion molecule 1] With or Without DAF [decay accelerating factor] Expressing Tumours.
Phase of Trial: Phase I
Latest Information Update: 16 May 2017
At a glance
- Drugs CVA 21 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Prostate cancer; Solid tumours
- Focus Adverse reactions
- 09 Apr 2013 Primary endpoint `patient tolerability' has been met, according to a Viralytics media release.
- 09 Apr 2013 Results reported in a Viralytics media release.
- 09 Nov 2012 Results were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in November 2012, according to a Viralytics media release.